CORRIGENDUM

DOI: 10.3892/ijo.2016.3749

Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma

WEI YANG, XIAOYUAN WANG, WEI ZHENG, KEDONG LI, HAOFENG LIU and YUEMING SUN

Int J Oncol 42: 690-698, 2013; DOI: 10.3892/ijo.2012.1741

Following the publication of this article, an interested reader drew to our attention anomalies associated with the data shown in Fig. 2, which presented the mRNA and protein expression levels of tropomyosin 1 (TPM1) in HuCCT1 cells. Essentially, the control bands for $\alpha\text{-tubulin}$ had been duplicated across from Fig. 2A to Fig. 2B, and from Fig. 2D to Fig. 2E [the experiments showing treatment of the cells with (A) manumycin A, (B) U0126, (D) 5-aza-2-deoxycytidine (DAC) and (E) trichostatin A (TSA)], respectively. After having re-examined our original data, we realize that the figure was compiled incorrectly, and have returned to our source data. A corrected version of Fig. 2 is presented here, showing the correct control $\alpha\text{-tubulin}$ data for Fig. 2A and E, as they ought to have appeared. This error did not overall affect the conclusions reported in the study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. Furthermore, we regret any inconvenience this mistake has caused.




Figure 2. TPM1 mRNA expression and protein expression in HuCCT1 cells. (A) HuCCT1 cells were treated with 5 and 10 μ mol/l manumycin A for 24 h. (B) HuCCT1 cells were treated with 5 and 10 μ mol/l U0126 for 24 h. (C) HuCCT1 cells were treated with 20 and 50 μ mol/l LY294002 for 24 h. (D) HuCCT1 cells were treated with 1 and 5 μ mol/l DAC for 24 h. (E) HuCCT1 cells were treated with 0.1 and 0.25 μ mol/l TSA for 24 h. *P<0.05. TPM1, tropomyosin 1; DAC, 5-aza-2-deoxycytidine; TSA, trichostatin A.